A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
El-Rayes
B F
BF
Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI. Electronic address: belraye@emory.edu.
Zalupski
M
M
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.
Bekai-Saab
T
T
Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, Arthur-James Cancer Center, Columbus, OH.
Heilbrun
L K
LK
Department of Biostatisics, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Hammad
N
N
Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Patel
B
B
Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Urba
S
S
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.
Shields
A F
AF
Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Vaishampayan
U
U
Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Dawson
S
S
Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Almhanna
K
K
Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Smith
D
D
Department of Biostatisics, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Philip
P A
PA
Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.